Plasma cell myeloma
RecruitingStudy on the Safety and Effectiveness of BGB-11417 Alone and with Dexamethasone, Carfilzomib, Daratumumab, or Pomalidomide for Patients with Relapsed or Refractory Multiple Myeloma
Study on the Safety and Effectiveness of BGB-11417 Alone and with Dexamethasone, Carfilzomib, Daratumumab, or Pomalidomide for Patients with Relapsed or Refractory Multiple Myeloma
- Disease:Plasma cell myeloma
- Substances:CarfilzomibDaratumumab+3
Germany- Participants:18–64 years · 65+ years
- Substances:Carfilzomib
- Sponsor:BeOne Medicines AG








